Company Overview

March 2024



Safe Harbor Statement

Certain statements in this presentation, including responses to questions, contain or may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue", the negative of these terms or other similar expressions, or the use of future dates, although not all forward-looking statements may include, but are not limited to, statements regarding: our estimates of the annual total addressable global market for our product and service offerings; our expectations about market trends, new product timing and success, and our anticipated future operating results.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm's ability to raise additional capital to fund its existing operations and debt service obligations; Vapotherm's ability to comply with its financial covenants, execute on its path to profitability initiative, convert excess inventory into cash and fund its business and otherwise continue as a going concern through 2024; Vapotherm has incurred losses in the past and may be unable to achieve or sustain profitability in the future; risks associated with its manufacturing operations in Mexico; Vapotherm's dependence on sales generated from its High Velocity Therapy systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market; the ability for High Velocity Therapy systems to gain increased market acceptance; Vapotherm's inexperience directly marketing and selling its products; the potential loss of one or more suppliers and dependence on its new third party manufacturer; Vapotherm's susceptibility to seasonal fluctuations; Vapotherm's failure to comply with applicable United States and foreign regulatory requirements; the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain or enforce patent or other intellectual property protection for its products; the impact of COVID on its business, including its supply chain; risks in holding Vapotherm stock in light of trading on the OTCQX tier of the OTC Markets; and the other risks and uncertainties included under the heading "Risk Factors" in Vapotherm's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024, and its subsequent filings with the SEC. The




A global healthcare technology company helping patients with **respiratory distress**

The <u>only</u> mask-free, clinically validated alternative to current standard of care for the treatment of respiratory distress

Clinically Validated

4.2M+ Patients Treated 37K+ Installed Base








Why We Win







Compelling Clinical Data



The Precision Flow does not provide the total ventilatory requirements of patients

A 204-patient, multi-site prospective randomized controlled trial showed Vapotherm high velocity therapy is a safe and effective alternative to NIPPV for all cause respiratory distress patients

Doshi, Pratik et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. Annals of Emergency Medicine, 2018. Published online ahead of print. https://www.ncbi.nlm.nih.gov/pubmed/29310868.



HYPERACT - Randomized Multi-Center Clinical Trial

Locations: 7 hospitals

- 3 academic
- 3 community
- 1 military



Population: ED Mod- Severe COPD PCO₂ > 60 mmHg and pH 7.0 - 7.35

1:1 High velocity therapy (n=36) or NIPPV (n=32)

Mean Values (at Randomization)

	High Velocity Therapy	NIPPV
PCO ₂	77.8	76.5
рН	7.27	7.27
Dyspnea Score	5.4	5.6

Primary Outcome:

 Dyspnea severity 4 hours after initiation of treatment measured by modified Borg Scale.³⁻⁴

Secondary Outcomes:


- Physiologic parameters changes: SpO₂ & VS
- VBG parameter changes: PCO₂, pH
- Dyspnea at 30 min, 60 min & need for intubation
- Patient and physician perceptions of clinical stability & comfort

3. Yamane, D.P., et. al.(2024), *High-flow Nasal Insufflation vs. Non-Invasive Ventilation for Acute Exacerbation of COPD: A Randomized Clinical Trial.*. Crit Care Med, 2024. 52(1): p. s21.

4. Vapotherm Doc REPO-001430: HYPERACT Clinical Trial Summary and Report



HYPERACT: Noninferior Changes in pH and PCO2 Values




4 Hour Mean Values

For spontaneously breathing patients. High velocity therapy does not provide total ventilatory		High Velocity Therapy	NiPPV	<i>p</i> value	
requirements of the patient. It is not a ventilator.	рН	7.31 (31)	7.31 (25)	0.498	
	PCO ₂	68.76 (31)	67.29 (25)	0.631	



HYPERACT: Patient Reported Overall Level of Discomfort

Patient Reported Level of Discomfort



HVT 2.0 Confidence in Care, Throughout the Hospital




- Mask-free respiratory support
- Integrated blower and transfer capabilities
- Large, intuitive touchscreen
- Fully assembled disposable enhances efficiency
- Single use disposable for 3-45 lpm
- Optimized to work with premium ProSoft cannula
- Nurse call and EMR connectivity
- Integrated Oxygen Assist Module vs. separate module
- Sets stage for home and transport



Vapotherm Product Roadmap:

Creating a Digitally Enabled Care Ecosystem for Complex Lung Disease Patients





Significant Progress Made on Path to Profitability Plan Since Launch in Early '22

Financial Results: \$ in Ms	Actual													
-	20	Q'22	3	Q'22	4	Q'22	1	Q'23	2	Q'23	3	Q'23	40	\ '23
Revenue Growth*										34%		18%		6%
<i>Revenue Growth* 2Q'23-4Q'23 vs 2Q'22-4Q'22</i>														17%
Gross Margin		18%		14%		28%		35%		43%		40%		47%
Cash OpEx*	\$	24	\$	22	\$	18	\$	16	\$	14	\$	12	\$	12
Adjusted EBITDA*	\$	(20)	\$	(18)	\$	(12)	\$	(9)	\$	(6)	\$	(6)	\$	(2)
Inventory	\$	38	\$	36	\$	33	\$	29	\$	25	\$	23	\$	23
Cash Burn From Operations**	\$	(20)	\$	(19)	\$	(11)	\$	(10)	\$	(7)	\$	(3)	\$	(4)

*Excludes revenue from Vapotherm Access call center business which the company exited in Q4'22. A reconciliation to GAAP revenue, Cash OpEx and Adjusted EBITDA can be found on the Company's website: www.Vapotherm.com

**Reflects cash used in operations from the Company's statements of cash flows. The Company's financial statements including statements of cash flows can be found on the Company's website: www.Vapotherm.com



Building Long Term, Sustainable Competitive Advantage

Disruptive HIGH VELOCITY THERAPY for treating respiratory distress

\$8 Billion **MARKET** opportunity

Rich product pipeline – HOME, DIGITAL

Compelling body of Level 1 CLINICAL DATA

Global respiratory SALES FORCE

Robust and growing IP PATENT PORTFOLIO

Recurring REVENUE MODEL

Experienced management **TEAM** and board



